Nautilus Biotechnology(NAUT) - 2024 Q4 - Annual Results

Financial Performance - Net loss for Q4 2024 was $17.6 million, compared to a net loss of$17.0 million in Q4 2023; the total net loss for the fiscal year 2024 was $70.8 million, up from$63.7 million in 2023[4] - Operating expenses for Q4 2024 were $20.0 million, unchanged from Q4 2023, while total operating expenses for the fiscal year 2024 increased by$5.3 million or 7% to $81.5 million compared to$76.2 million in 2023[3] - Research and development expenses for the fiscal year 2024 were $50.5 million, an increase from$47.3 million in 2023[15] - General and administrative expenses for the fiscal year 2024 rose to $31.0 million from$28.9 million in 2023[15] - Interest income for the fiscal year 2024 was $10.8 million, down from$12.6 million in 2023[15] - The accumulated deficit increased to $273.0 million as of December 31, 2024, compared to$202.2 million in 2023[13] - The total assets decreased to $242.7 million as of December 31, 2024, from$305.6 million in 2023[13] Cash and Investments - Cash, cash equivalents, and investments totaled $206.3 million as of December 31, 2024, expected to provide a runway through 2027[5][9] Strategic Initiatives - A headcount reduction of approximately 16% was announced to align resources with key development goals and extend the cash runway[8] - The company announced a projected launch of its proteome analysis platform in late 2026, reflecting ongoing development efforts[8]